Last reviewed · How we verify
Standard Prophylaxis
Standard Prophylaxis is a treatment that prevents the occurrence of a specific condition.
Standard Prophylaxis is a treatment that prevents the occurrence of a specific condition. Used for Prevention of infectious diseases.
At a glance
| Generic name | Standard Prophylaxis |
|---|---|
| Also known as | Cyclosporine (CsA),Methotrexate (MTX), Mycopherol ester (MMF) and Antithymic Globulin |
| Sponsor | The First Affiliated Hospital of Soochow University |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The exact mechanism of Standard Prophylaxis is not well-documented, but it is believed to work by targeting a specific biological pathway. This pathway is thought to play a crucial role in the development of the condition being prevented.
Approved indications
- Prevention of infectious diseases
Common side effects
- Allergic reactions
Key clinical trials
- Screening and Multiple Intervention on Lung Epidemics (PHASE2)
- A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer (PHASE2)
- A Self-management Program to Prevent Falls in People With Multiple Sclerosis (NA)
- Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES) (NA)
- Group-Based Exercise Intervention to Prevent Cognitive and Motor Decline (NA)
- Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID) (PHASE1, PHASE2)
- Habit Building Software Application to Increase Engagement of Vulnerable Populations in the National Diabetes Prevention Program (NDPP) Lifestyle Change Program (LCP) (NA)
- Predictive Validity and Clinical Utility of an Ultrasound-based Quantitative Risk Score for Pressure Injury in Critically Ill Patients: A Two-Phase Sequential Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard Prophylaxis CI brief — competitive landscape report
- Standard Prophylaxis updates RSS · CI watch RSS
- The First Affiliated Hospital of Soochow University portfolio CI